Eli Lilly and Company (NYSE:LLY) Reaches New 1-Year High at $919.29

Shares of Eli Lilly and Company (NYSE:LLYGet Free Report) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $919.29 and last traded at $919.29, with a volume of 38523 shares trading hands. The stock had previously closed at $914.57.

Analyst Ratings Changes

Several analysts have issued reports on LLY shares. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, July 1st. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Bank of America reiterated a “buy” rating and issued a $1,000.00 price target on shares of Eli Lilly and Company in a research note on Monday, June 24th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $1,001.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, July 3rd. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $816.78.

Get Our Latest Stock Analysis on Eli Lilly and Company

Eli Lilly and Company Trading Up 1.7 %

The firm has a market cap of $887.06 billion, a PE ratio of 137.46, a P/E/G ratio of 2.00 and a beta of 0.41. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The company’s 50 day moving average price is $838.34 and its two-hundred day moving average price is $757.52.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period in the prior year, the company posted $1.62 EPS. The firm’s revenue for the quarter was up 26.0% on a year-over-year basis. As a group, sell-side analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 194,978 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the completion of the sale, the insider now owns 97,583,810 shares of the company’s stock, valued at $86,450,473,117.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, major shareholder Lilly Endowment Inc sold 194,978 shares of Eli Lilly and Company stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $885.91, for a total value of $172,732,959.98. Following the completion of the sale, the insider now directly owns 97,583,810 shares in the company, valued at $86,450,473,117.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the transaction, the executive vice president now directly owns 25,428 shares in the company, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Insiders sold a total of 1,004,704 shares of company stock valued at $869,479,116 in the last three months. Company insiders own 0.13% of the company’s stock.

Institutional Trading of Eli Lilly and Company

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Lipe & Dalton purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $26,000. Tidemark LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $29,000. Core Wealth Advisors Inc. boosted its holdings in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after acquiring an additional 32 shares in the last quarter. Lynx Investment Advisory purchased a new stake in shares of Eli Lilly and Company during the second quarter worth about $32,000. Finally, Frank Rimerman Advisors LLC acquired a new stake in Eli Lilly and Company in the 4th quarter worth approximately $37,000. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Recommended Stories

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.